Patents by Inventor Cameron J Turtle

Cameron J Turtle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11815514
    Abstract: Provided are methods, kits and compositions related to toxicity associated with administration of cell therapy for the treatment of diseases or conditions, e.g., cancer, including methods for use in predicting and treating a toxicity. In some embodiments, the toxicity is a neurotoxicity or cytokine release syndrome (CRS), such as a severe neurotoxicity or a severe CRS. The methods generally involve detecting a parameter of a biomarker or individually a parameter of each biomarker in a panel of biomarkers, such as a concentration, amount or activity, and comparing the detected parameter to a reference value for the parameter to determine if the subject is at risk for developing the toxicity, such as neurotoxicity or CRS or severe neurotoxicity or severe CRS.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: November 14, 2023
    Assignees: Juno Therapeutics, Inc., Fred Hutchinson Cancer Research Center
    Inventors: He Li, Mark J. Gilbert, David Maloney, Stanley R. Riddell, Cameron J. Turtle
  • Publication number: 20230218669
    Abstract: Combination therapies that include (i) an immune cell that expresses a chimeric antigen receptor (CAR) or similar molecule and (ii) a compound that preserves or potentiates the in vivo actions of tumor necrosis factor alpha (TNF?) against cancer cells are described. The combination therapies result in the killing of antigen-negative cells in the vicinity of immunotherapy targeted-antigen-positive cells reducing the survivability of escape variants and providing other benefits.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 13, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Cameron J. Turtle, Salvatore Fiorenza
  • Publication number: 20230220103
    Abstract: Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of human CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion/activation processes utilizing IL-2, IL-7, IL-15, and/or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.
    Type: Application
    Filed: March 31, 2021
    Publication date: July 13, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Cameron J. Turtle, Roland B. Walter, George S. Laszlo, Salvatore Fiorenza
  • Publication number: 20230158164
    Abstract: Provided are methods and compositions directed to the treatment of an individual having cancer by (i) administering to the individual an adoptive cellular immunotherapy composition comprising CAR T cells and (ii) administering to the individual an interleukin-15 receptor agonist, such as, for example, a long-acting interleukin-15 receptor agonist.
    Type: Application
    Filed: April 4, 2020
    Publication date: May 25, 2023
    Inventors: Antonio Mario Querido Marcondes, Peter Benedict Kirk, Takahiro Miyazaki, Cameron J. Turtle, Stanley R. Riddell, Cassie K. Chou, Simon P. Fräßle
  • Publication number: 20230151094
    Abstract: Chimeric antigen receptors (CARs) with binding domains derived from a novel suite of CD33-binding antibodies are described. The CARs include optimized short and intermediate spacer regions. The current disclosure also provides methods of cell expansion/activation processes utilizing IL-2, IL-7, IL-15, and/or IL-21 that improve cellular proliferation and cell lysis of the CARs as described.
    Type: Application
    Filed: March 31, 2021
    Publication date: May 18, 2023
    Applicant: Fred Hutchinson Cancer Center
    Inventors: Cameron J. Turtle, Roland B. Walter, George S. Laszlo, Salvatore Fiorenza
  • Patent number: 11397183
    Abstract: The instant disclosure provides biomarkers and methods for identifying subjects at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both after adoptive immunotherapy to guide preemptive intervention, modified therapy, or the like. For example, adverse event biomarkers may be measured in a subject before pre-conditioning chemotherapy, before immunotherapy (e.g., adoptive immunotherapy infusion comprising a chimeric antigen receptor (CAR) modified T cell), or shortly after pre-conditioning chemotherapy and/or immunotherapy. Exemplary biomarkers include temperature, cytokine levels and endothelial activation biomarkers, such as angiopoietin 2, von Willebrand factor (vWF), ratio of angiopoietin 2 to angiopoietin 1, and ratio of ADAMTS13 to vWF. Also provided are methods of treating subjects identified as at risk of developing cytokine release syndrome (CRS), neurotoxicity, or both to minimize such potential adverse events.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: July 26, 2022
    Assignees: Fred Hutchinson Cancer Center, University of Washington, Bloodworks Northwest
    Inventors: W. Conrad Liles, Cameron J. Turtle, David G. Maloney, Stanley R. Riddell, Mark M. Wurfel, Jose Lopez, Dominic Chung, Junmei Chen
  • Patent number: 10653756
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 19, 2020
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Cameron J. Turtle, Stanley R. Riddell
  • Publication number: 20180243386
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Application
    Filed: February 23, 2018
    Publication date: August 30, 2018
    Inventors: Cameron J. Turtle, Stanley R. Riddell
  • Patent number: 9931384
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: April 3, 2018
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Cameron J. Turtle, Stanley R. Riddell
  • Publication number: 20160045580
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Application
    Filed: July 27, 2015
    Publication date: February 18, 2016
    Inventors: Cameron J. Turtle, Stanley R. Riddell
  • Patent number: 9090875
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Grant
    Filed: January 28, 2009
    Date of Patent: July 28, 2015
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Cameron J. Turtle, Stanley R. Riddell
  • Publication number: 20110059012
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Application
    Filed: January 28, 2009
    Publication date: March 10, 2011
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Cameron J Turtle, Stanley R. Riddell